The complexities of obesity and diabetes with the development and progression of pancreatic cancer
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer (PC) is one of the most lethal malignant diseases with the worst prognosis. It is ranked as the fourth leading cause of cancer-related deaths in the United States. Many risk factors have been associated with PC. Interestingly, large numbers of epidemiological studies suggest that obesity and diabetes, especially type-2 diabetes, are positively associated with increased risk of PC. Similarly, these chronic diseases (obesity, diabetes and cancer) are also a major public health concern. In the U.S. population, 50 percent are overweight, 30 percent are medically obese and 10 percent have diabetes mellitus (DM). Therefore, obesity and DM have been considered as potential risk factors for cancers; however, the focus of this article is restricted to PC. Although the mechanisms responsible for the development of these chronic diseases leading to the development of PC are not fully understood, the biological importance of the activation of insulin, insulin like growth factor-1 (IGF-1) and its receptor (IGF-1R) signaling pathways in insulin resistance mechanism and subsequent induction of compensatory hyperinsulinemia has been proposed. Therefore, targeting insulin/IGF-1 signaling with anti-diabetic drugs for lowering blood insulin levels and reversal of insulin-resistance could be useful strategy for the prevention and/or treatment of PC. A large number of studies have demonstrated that the administration of anti-diabetic drugs such as metformin and thiazolidinediones (TZD) class of PPAR-γ agonists decreases the risk of cancers, suggesting that these agents might be useful anti-tumor agents for the treatment of PC. In this review article, we will discuss the potential roles of metformin and TZD anti-diabetic drugs as anti-tumor agents in the context of PC, and will further discuss the complexities and the possible roles of microRNAs (miRNAs) in the pathogenesis of obesity, diabetes and PC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 3×
“The oxidative stress created by chronic high exposure to glucose and lipids and decreased activity of antioxidants in the accumulated adipose tissue leads to dysfunction of adipose tissues such as altered expression of adipokines and cytokines [103].”
BackgroundInfluentialMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“resistance is one of the earliest negative effects of obesity, and is associated with the early altered glucose metabolism, chronic inflammation, oxidative stress and decreased levels of adipose hormone adiponectin and PPAR-γ, key regulators for adipogenesis [46–49].”
BackgroundRenehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 1×
“In most cell types, these substrates mediate the PI3K/Akt/mTOR signaling pathway [147], which is known to play a pivotal role in the proliferation and survival of PC cells [148,149].”
BackgroundElevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“tissues, including skeletal muscles and adipose tissue [157].”
BackgroundObesity-induced inflammatory changes in adipose tissue
Wellen, K. E., & Hotamisligil, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320514 · Cited by 1,823
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Inflammation and cancer: how hot is the link?
Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.029 · Cited by 1,312
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 1×
“In vitro and in vivo studies show that metformin can block tumor growth by inactivation of breast cancer stem-like cells and epithelial–mesenchymal transition (EMT) phenotype, and these cells are believed to be the root cause of tumor recurrence and metastasis [186,187].”
BackgroundType-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“Numerous epidemiological studies have demonstrated that the administration of metformin in DM patients exhibits a protective effect by decreasing incidence of different tumors and improving prognosis of patients with cancer [160–164].”
BackgroundBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
β-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“One recent study showed that women taking metformin had a pathologic complete response rate of 24 percent as compared to 8 percent of women who were not [169].”
ResultSahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Ye, J., Gao, Z., Yin, J., & He, Q. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2007 · Cited by 840
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · cited 1×
“correlated with the high risk of cancers including PC [87,88,95–101].”
Obesity and cancer: the role of dysfunctional adipose tissue
van Kruijsdijk, R. C. M., van der Wall, E., & Visseren, F. L. J. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0372 · Cited by 715
Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633
Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.039 · Cited by 621 · cited 1×
“Other recent studies also provide supportive evidence documenting that DM is positively associated with increased risk of PC [54,142–144].”
ResultHemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 1×
“Human insulin users have been found to have an increased risk for the development of cancers including PC [150,151].”
BackgroundMetformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Il'yasova, D., Colbert, L. H., Harris, T. B., Newman, A. B., Bauer, D. C., Satterfield, S., & Kritchevsky, S. B. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0316 · Cited by 479
Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?
Trayhurn, P., Wang, B., & Wood, I. S. (2008) · British Journal of Nutrition · doi:10.1017/s0007114508971282 · Cited by 464
Association between adiponectin and mediators of inflammation in obese women
Engeli, S., Feldpausch, M., Gorzelniak, K., Hartwig, F., Heintze, U., Janke, J., Möhlig, M., Pfeiffer, A. F. H., Luft, F. C., & Sharma, A. M. (2003) · Diabetes · doi:10.2337/diabetes.52.4.942 · Cited by 422 · cited 1×
“Suchhormones are knownasadipokines,whichplays important roles in the secretion, regulation, andmaintenance of normalmetabolic and immune function [50,63,64].”
BackgroundAnisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
Circulating Levels of Inflammatory Cytokines and Risk of Colorectal Adenomas
Kim, S., Keku, T. O., Martin, C., Galanko, J., Woosley, J. T., Schroeder, J. C., Satia, J. A., Halabi, S., & Sandler, R. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2924 · Cited by 298
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Rozengurt, E., Sinnett-Smith, J., & Kisfalvi, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2229 · Cited by 247 · cited 8×
“Additional evidence showed that metformin can inhibit PC cell growth and proliferation by disruption of insulin/IGF-1R and GPCR crosstalk through the activation of AMPK [189,191].”
BackgroundInfluentialEffects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes
Lolmède, K., Durand de Saint Front, V, Galitzky, J., Lafontan, M., & Bouloumié, A. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802407 · Cited by 224 · cited 2×
“Obesity-induced hypoxia, especially in adipose tissue, is involved in the development of local and systemic insulin resistance, the up-regulation of chronic inflammation, reduced adiponectin and increased leptin gene expressions [122–124].”
BackgroundSulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185 · cited 1×
“Animal studies have also demonstrated that metformin can inhibit tumor growth in xenograft models [171–174].”
BackgroundPPARγ as a therapeutic target for tumor angiogenesis and metastasis
Panigraphy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.2014 · Cited by 137 · cited 1×
“Secondly, the activation of PPAR-γ can inhibit TNF-α, IL-6, IL-8, PAI-1, VEGF, COX2, MMPs, uPA, NF-κB, AP-1, STAT, and leptin [212,214–223].”
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Koro, C., Barrett, S., & Qizilbash, N. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1352 · Cited by 107 · cited 1×
“The majority of the studies showed inconsistent or inconclusive results [164,204].”
Result
Cited by
Dietary phytochemicals and their potential effects on obesity: A review
González-Castejón, M., & Rodriguez-Casado, A. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.07.004 · Cited by 372
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C. J., Hassan, M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 305
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & Selagamsetty, R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 275
Mohammed, A., Janakiram, N. B., Brewer, M., Ritchie, R. L., Marya, A., Lightfoot, S., Steele, V. E., & Rao, C. V. (2013) · Translational Oncology · doi:10.1593/tlo.13556 · Cited by 142
Karnevi, E., Said, K., Andersson, R., & Rosendahl, A. H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-235 · Cited by 99
Metadata
- Authors
- Bao, B., Wang, Z., Li, Y., Kong, D., Ali, S., Banerjee, S., Ahmad, A., & Sarkar, F. H.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 1815
- Issue
- 2
- Pages
- 135-146
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2000977663
- Cited by
- 94
- References
- 43
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.